Merus (MRUS) Competitors $39.45 -0.20 (-0.50%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MRUS vs. QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, and ELANShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Merus vs. Qiagen Vaxcyte Ascendis Pharma A/S Roivant Sciences Revolution Medicines Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Merus (NASDAQ:MRUS) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership. Does the media refer more to MRUS or QGEN? In the previous week, Merus had 1 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for Merus and 13 mentions for Qiagen. Merus' average media sentiment score of 0.75 beat Qiagen's score of 0.73 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 2 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, MRUS or QGEN? Qiagen has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$43.95M61.45-$154.94M-$3.95-9.99Qiagen$1.97B5.34$341.30M$0.39117.94 Is MRUS or QGEN more profitable? Qiagen has a net margin of 4.73% compared to Merus' net margin of -680.61%. Qiagen's return on equity of 13.43% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Qiagen 4.73%13.43%8.10% Which has more volatility & risk, MRUS or QGEN? Merus has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MRUS or QGEN? 96.1% of Merus shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend MRUS or QGEN? Merus currently has a consensus target price of $85.64, indicating a potential upside of 117.08%. Qiagen has a consensus target price of $51.50, indicating a potential upside of 11.96%. Given Merus' stronger consensus rating and higher probable upside, research analysts clearly believe Merus is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14Qiagen 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the MarketBeat Community favor MRUS or QGEN? Merus received 104 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 67.11% of users gave Merus an outperform vote while only 60.73% of users gave Qiagen an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes35367.11% Underperform Votes17332.89% QiagenOutperform Votes24960.73% Underperform Votes16139.27% SummaryMerus beats Qiagen on 11 of the 19 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.70B$6.58B$5.35B$9.06BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-9.999.8389.4817.34Price / Sales61.45307.731,251.60134.53Price / CashN/A61.4443.7535.97Price / Book6.396.055.324.80Net Income-$154.94M$154.62M$122.60M$224.91M7 Day Performance-10.03%-1.70%0.88%1.90%1 Month Performance-7.05%2.75%4.81%5.08%1 Year Performance23.82%2.60%27.90%21.15% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.9828 of 5 stars$39.45-0.5%$85.64+117.1%+22.7%$2.70B$43.95M-9.9937Short Interest ↓News CoverageQGENQiagen4.0945 of 5 stars$45.90+2.7%$51.50+12.2%-0.2%$10.47B$1.97B117.695,967Short Interest ↓News CoveragePCVXVaxcyte1.9841 of 5 stars$80.35-0.9%$145.71+81.3%+35.7%$10.01BN/A-17.47160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6129 of 5 stars$131.72+2.0%$192.07+45.8%-3.2%$7.99B$327.43M-16.30640Short Interest ↓ROIVRoivant Sciences3.6806 of 5 stars$10.67+0.4%$17.93+68.0%+3.6%$7.77B$129.13M1.89860Insider TradeOptions VolumePositive NewsRVMDRevolution Medicines4.4701 of 5 stars$42.24+1.1%$66.25+56.8%+50.2%$7.11B$742,000.00-11.77250News CoverageLNTHLantheus4.5418 of 5 stars$94.41-1.5%$131.86+39.7%+65.5%$6.56B$1.50B15.71700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6641 of 5 stars$100.10+14.5%$122.72+22.6%+38.6%$6.36B$434.42M-47.44640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionBBIOBridgeBio Pharma4.0863 of 5 stars$32.69+12.4%$48.08+47.1%-8.5%$6.18B$217.77M-13.56400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.5041 of 5 stars$31.78-5.5%$80.62+153.7%-45.5%$5.80B$520.18M-33.451,800Short Interest ↓News CoverageELANElanco Animal Health4.415 of 5 stars$11.55+1.0%$16.43+42.2%-18.8%$5.71B$4.45B28.889,800 Related Companies and Tools Related Companies Qiagen Competitors Vaxcyte Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors Lantheus Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Legend Biotech Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRUS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
